OBJECTIVES: : Proton pump inhibitors (PPIs) are essential components schemes of antyhelicobacter therapy (AT) of peptic ulcer disease. The aim of research - to determine the costs of the use of PPIs in the traditional triple schemes AT (first and second line) of the working age patients with a duodenal ulcer in Ukraine. The objects of research - preparations of omeprazole, pantoprazole, rabeprazole, lansoprozol, ezomeprazol, which are present in Ukraine.   METHODS: Cost analysis on the use of PPIs in the schemes of AT was performed per one patient for 14 days with the daily doses of drugs: omeprazole - 40 mg, pantoprazole - 80 mg, rabeprazole - 40 mg, lansoprozol - 60 mg, ezomeprazol - 40 mg (according to the recommendations of the "Maastricht IV", 2010). For determining the costs only the costs of the PPIs were taken into account. The prices of drugs were taken from the information system "Drugs" of Company "Morion" (December, 2012). The currency ratio of UAH to dollar (USA) on 10.12.12 was 7.99:1. To determine the range of costs for use of PPIs determined their trade names with the minimum and maximum costs for the AT.   RESULTS: The range of costs for use of PPIs in the traditional triple schemes AT in Ukraine is wide enough, respectively: omeprazole -  1.15 - 19.15 $, pantoprazole - 5.11 - 49.28 $, lansoprozol - 5.14 - 10.66 $, rabeprazole - 4.27 - 63.40$, ezomeprazol 1.81 - 36.42$.   CONCLUSIONS: Costs only for the use of PPIs in the schemes of AT of duodenal ulcer can be quite high in Ukraine. In this regard, the choice of PPIs for inclusion in the schemes of AT is advisable to use the results of pharmacoeconomic studies that will optimize the costs of the payer.